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Background: This study analyzed regularity in the daily dosage of antidepressants taken by patients with bipolar
disorder and identified the factors associated with irregularity.
Methods: Daily self-reported medication dosage taken and mood ratings were available from 144 patients who
received treatment as usual. All 144 patients took the same antidepressant for at least 100 days. One hundred
eleven of these patients were also taking a mood stabilizer. Approximate entropy (ApEn) was used to measure serial
regularity in daily dosage. Regularity is the tendency that values within a time series remain the same on
incremental comparisons. Drug holidays (missing three or more consecutive days) were also determined.
Generalized estimating equations (GEE) were used to estimate if any demographic or clinical variables were
associated with regularity.
Results: Although the mean percent of days missing doses was only 18.6%, there was a wide range of regularity in
the daily antidepressant dosage. Drug holidays were common, occurring in 41% of the analyses. Factors
significantly associated with irregularity were as follows: total number of psychotropic medications (p = 0.005),
pill burden (p = 0.005), and depression (p = 0.015). Neither the percent of days missing doses nor the drug holidays
were associated with any demographic or clinical factors. For patients taking both antidepressants and mood
stabilizers, there was no significant difference in regularity in daily dosage between these drugs.
Discussion: There can be considerable irregularity in daily dosage despite a low percent of days missing doses.
Medication regimen complexity and depressed mood are associated with increased irregularity. Daily regularity in
drug dosage may be more dependent on the individual than on the specific drug. Research on the clinical impact
of irregularity in daily dosage of antidepressants is needed.Background
Patients with bipolar disorder are expected to take many
drugs for long periods of time. Polypharmacy is pre-
scribed to about two thirds of patients with bipolar dis-
order in the USA and one half of those in Europe
(Baldessarini et al. 2008a; Bauer et al. 2013a; Goldberg
et al. 2009; Hayes et al. 2011; Quante et al. 2010). On
entry to the STEP-BD study, 40% of the 4,035 patients
were receiving three or more psychotropic drugs
(Goldberg et al. 2009). The drugs prescribed most* Correspondence: rita.bauer@uniklinikum-dresden.de
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in any medium, provided the original work is pfrequently for bipolar disorder are mood stabilizers and
antidepressants (Baldessarini et al. 2006; Baldessarini
et al. 2008a; Bauer et al. 2013a; Greil et al. 2012; Hayes
et al. 2011; Haeberle et al. 2012). Despite ongoing dis-
agreement as to the role of antidepressants in the treat-
ment of bipolar disorder (Altshuler et al. 2003; Ghaemi
et al. 2008; Möller and Grunze 2000; Pacchiarotti et al.
2013), long-term prescribing of antidepressants remains
widespread in clinical practice. In recent international
studies, about half the patients were prescribed antide-
pressants either as part of a polypharmacy regimen or as
monotherapy (Baldessarini et al. 2006; Baldessarini et al.
2008a; Haeberle et al. 2012; Quante et al. 2010; Sussman
et al. 2012).Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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mains a problem in almost half of patients with chronic ill-
ness regardless of specific diagnosis or drug (Briesacher
et al. 2008; Haynes et al. 2008). About 40% of patients with
bipolar disorder do not follow instructions for taking their
medications, with most having intermittent or partial ad-
herence with the prescribed dosing regimen (Lingram and
Scott Lingam and Scott 2002). Both the therapeutic and
side effects of a drug depend on the dosage strength and
the dosing interval, and deviation from the prescribed regi-
men may result in a poor medication response (Urquhart
1996; Urquhart 1997). We previously found considerable ir-
regularity in the daily dosage of mood stabilizers taken by
patients who only failed to take medication on 14% of days
(Bauer et al. 2013b). Regularity, as measured using approxi-
mate entropy (ApEn), is the tendency that values within a
time series remain the same on incremental comparisons
(Pincus et al. 1991). The purpose of this investigation was
to analyze the regularity in the daily antidepressant dosage
taken by patients with bipolar disorder based on self-
reported data, and to evaluate factors that may influence
regularity.
Methods
All data were obtained from an ongoing, long-term nat-
uralistic study in which patients with bipolar disorder re-
corded mood, sleep, and medications taken daily (Bauer
et al. 2012). Patients were aged 18 years or older, diag-
nosed with bipolar disorder using DSM-IV criteria, and
agreed to record mood, sleep, and medications daily
using ChronoRecord software on a home computer for
6 months. The diagnosis was made by the prescribing
psychiatrist at a clinical interview. Throughout the study,
all patients remained under the care of a psychiatrist
and received pharmacologic treatment as usual. All par-
ticipants were volunteers who did not receive payment
and had access to a home computer. All provided writ-
ten informed consent, approved by the local Institutional
Review Board, prior to the study.
Data collection
All data were collected using the previously validated
ChronoRecord software in the patient's native language
(Bauer et al. 2004; Bauer et al. 2008). The participants
entered a daily mood rating using a 100-unit visual ana-
log scale that was calibrated to the extremes of mania
and depression that the patient ever experienced. The
daily self-ratings of hypomania and mania reflect activa-
tion levels for either euphoric or dysphoric mood (Bauer
et al. 2004). Based on the validation studies, a mood
entry of less than 40 was considered depression, 40 to
60 euthymia, and >60 hypomania/mania. Every day, the
patients also recorded their sleep, psychotropic medica-
tions taken, and any significant life events.The patient's bipolar disorder medications were entered
during ChronoRecord training by selecting from a list in
the software. The list displays the psychotropic medications
for each country by brand and generic name, including an-
tidepressants, mood stabilizers (lithium, valproate, lamotri-
gine, carbamazepine, or oxcarbazepine), antipsychotics,
benzodiazepines, insomnia medications, other anticonvul-
sants, thyroid hormones, and estrogens. If there was a pre-
scription change, the patient could modify the drugs taken
and could add a drug that was not included in the software
list. For each medication, the patient entered the total num-
ber of pills taken daily. Partial pills (1/4, 1/2, or 3/4) could
be entered for tablets, but not for capsules. The patient en-
tered a 0 if no pills were taken, and missing days of data
were treated as no pills taken. The software includes error
checking steps such as preventing entry of data for a future
date and requiring confirmation for the entry of a large
number of pills.
Regularity analysis
The analysis of regularity in daily medication dosage was
described previously (Bauer et al. 2013b) and is summa-
rized here. ApEn computes a single, non-negative number,
where 0 indicates a completely regular sequence and in-
creasing positive values indicate increasing levels of irregu-
larity (Pincus et al. 1991; Pincus et al. 1999). The estimated
value of the ApEn (m,r,N) depends on m the pattern length
used for prediction of the subsequent value, r the level of
noise filtering, and N the number of dosage values in the
run to be compared. The level of noise filtering was calcu-
lated as a percent of the individual subjects' standard devi-
ation. The ApEn parameters m = 1 day, r = 0.2 × SD in daily
antidepressant or mood stabilizer dosage, and N = 100 days
were used in this analysis. The same data length was used
for each ApEn analysis (Pincus et al. 1999). The value of
ApEn is dependent on the order of data in a time series
and changing the order of the data will likely change the
ApEn. In contrast, the traditional mean and standard devi-
ation will be identical for a set of values regardless of the
order of the data used in the calculation. ApEn is most use-
ful with partial adherence since the result would be 0 if a
patient discontinued treatment or made no changes and is
not largely affected by a prescription change if the new dos-
age is maintained (Bauer et al. 2013b).
Data
For each patient, for each antidepressant, the time span
for taking each antidepressant was determined. If the
time span was ≥ 100 days, the ApEn was calculated for
the first 100 days of data using the daily antidepressant
dosage taken. The database contained 109,287 days of
data from 475 patients who returned ≥ 30 days of data.
Starting with 475 patients, 244 (51.4%) of the patients
took an antidepressant for at least one day. Of these 244
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antidepressants for ≥ 100 days and were included in the
analysis. More than one ApEn analysis was completed if
patients took more than one antidepressant for
≥ 100 days. Thirty-six of the 144 patients were not in-
cluded in our prior analysis of regularity in daily mood
stabilizer dosage (Bauer et al. 2013b). Of the 144 pa-
tients, 111 were taking at least one antidepressant and at
least one mood stabilizer for ≥ 100 days. For these 111
patients, the ApEn analysis of the daily mood stabilizer







High school 18 (13.3)
Some college 41 (30.4)
College graduate 76 (56.3)
Age, n; mean ± SD 144; 42.9 ± 11.2
Age of onset, n; mean ± SD 135; 23.1 ± 11.6
Hospitalizations, n; mean ± SD 133; 2.6 ± 4.0
Years of illness, n; mean ± SD 135; 20.3 ± 12.3Statistical analysis
The demographic and clinical characteristics as measured
by the mood ratings and psychotropic medications taken
by the 144 patients were calculated. For each patient, the
percent of days with euthymic, depressed, and hypomanic/
manic mood were determined for each 100-day ApEn ana-
lysis period. For each patient, the mode of the daily number
of medications and the number of pills (pill burden) for all
psychotropic medications during the 100-day span were
calculated. Also, for each patient, the mode of the daily
antidepressant dosage was calculated for each patient for
each antidepressant taken in the 100-day span. The mode
is the most frequent value in a series of numbers and was
chosen as a proxy for the prescribed daily number of medi-
cations, pill burden, and daily dosage. A generalized esti-
mating equation (GEE) approach was used to adjust model
coefficients and standard errors for within-patient correl-
ation since a patient could take more than one antidepres-
sant or mood stabilizer. To estimate if any demographic or
clinical variables were associated with ApEn for antidepres-
sants, GEE models used ApEn as the dependent variable
with an independent working correlation structure (Pan
and Connett 2002). GEE models were also used to estimate
if demographic or clinical variables were associated with
the percent of days missing doses, or with taking drug holi-
days. For patients taking both antidepressants and mood
stabilizers, GEE models were used to estimate if the ApEn
was significantly different between these drugs. SPSS 20.0
(Armonk, NY, USA) was used for all calculations.Results
The demographic characteristics of the 144 patients are
shown in Table 1. The 144 patients took between one
and four antidepressants: 96 took one antidepressant, 39
took two antidepressants, 3 took three antidepressants,
and 6 took four antidepressants for a total of 207 ApEn
analyses. The 144 patients returned a mean of 390.5 ±
194 days of data. During the 207 100-day analysis pe-
riods, the 144 patients were depressed on average for
23.8% of days, euthymic for 69.5% of days, and hypo-
manic/manic for 6.7% of days.Medication overview
The 144 patients took a mean of 4.4 ± 2.1 psychotropic
medications daily with a mean pill burden of 7.6 ± 5.3.
The psychotropic drugs taken by the 144 patients are
shown in Table 2. The 144 patients took 20 different an-
tidepressants, of which 8 were included in ≥ 10 analysis
periods: bupropion in 40, venlafaxine in 28, escitalopram
in 24, citalopram in 17, sertraline in 14, duloxetine in 13,
paroxetine in 13, and fluoxetine in 11. During the 207
analysis periods, the mean percent of days missing doses
of antidepressant was 18.6% ± 22.0%. There was no asso-
ciation between the percent of days missing doses of
antidepressant and the pill burden (p = 0.396), total
number of medications (p = 0.086), percent of days de-
pressed (p = 0.070), percent of days euthymic (p = 0.135),
or the percent of days manic (p = 0.839).
There was at least 1 day of missing data in 136 (66%)
of the 207 analysis periods. One or more drug holidays,
defined as missing three or more consecutive days (Ur-
quhart 1997), was present in 85 (41.1%) of the analysis
periods. See Table 3. Of the 85 analysis periods, with at
least one drug holiday, more than one drug holiday was
present in 38 (44.7%). There was no significant associ-
ation between drug holidays and any demographic or
clinical values. Figure 1 provides examples of patients
Table 2 Patient medications (N = 144)
Value





Taking mood stabilizer, n (%) 106 (73.6)
Taking benzodiazepine, n (%) 33 (22.9)
Taking antipsychotic, n (%) 57 (39.6)
Total pill burdena, mean ± SD 7.6 ± 5.3
Total number of medicationsa, mean ± SD 4.4 ± 2.1
Antidepressantsc, mean daysb; mean dosage mg ± SD
Bupropionc 86; 277.3 ± 30.3
Citalopram 92; 37.4 ± 4.6
Duloxetine 77; 58.8 ± 6.0
Escitalopram 90; 15.3 ± 2.2
Paroxetine 87; 20.1 ± 4.1
Fluoxetine 90; 31.7 ± 6.6
Sertraline 85; 89.2 ± 9.1
Venlafaxine 82; 173.8 ± 11.9
aPsychiatric medications only. Calculated as mode for each patient.
bExcluding missing days.
cOnly antidepressants included in ≥10 analysis periods.
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cent of days missing doses, related to the missing days
and drug holidays.
Regularity analysis
The 207 ApEn results for antidepressants ranged be-
tween 0 and 1.04, with a mean of 0.21 (SD 0.19), with
120 (58%) between 0 and 0.2, 55 (27%) > 0.2 and ≤0.4,
and 32 (15%) > 0.4. Only 15% (n = 31) of the patients had
an ApEn of 0, meaning no change in the daily anti-
depressant dose across the 100-day analysis period. As
shown in Table 4, the total number of medications, the
pill burden, and depression were associated with in-
creased irregularity (larger ApEn), while euthymia was








aDrug holiday defined as missing three or more consecutive days.Antidepressants and mood stabilizer analysis
The 111 patients who were taking both a mood stabilizer
and an antidepressant took between one and four anti-
depressants: 72 took one antidepressant, 31 took two an-
tidepressants, 2 took three antidepressants, and 6 took
four antidepressants for a total of 164 ApEn analyses for
antidepressants. The 111 also took between one and
three mood stabilizers: 76 took one mood stabilizer, 32
took two mood stabilizers, and 3 took three mood stabi-
lizers for a total of 149 ApEn analyses for mood stabi-
lizers. In total, there were 313 ApEn analyses for those
taking both mood stabilizers and antidepressants. For
the 111 individuals, there was no significant difference
in the regularity for taking an antidepressant versus tak-
ing a mood stabilizer (p = 0.273).
Discussion
Across individuals, a wide range of irregularity in the
daily dosage of antidepressants was found among pa-
tients who were motivated to record mood daily and
who took medication on 81% of days. The irregularity
was primarily due to single-day omissions and changes
in daily dosage. Drug holidays were also common, with
at least one drug holiday occurring in 41% of the ana-
lysis periods. The lack of association between the per-
cent of days missing doses and either mood, number of
daily medications or pill burden suggests that regularity
and the percent of days missing doses are measuring dif-
ferent aspects of adherence (Bauer et al. 2013b). Regular-
ity, as measured by ApEn, should be used in conjunction
with summary statistics, as each provides separate
information.
Irregularity in daily dosage is important since it may
contribute to individual variation in drug response (Har-
ter and Peck 1991; Urquhart 1997; Vrijens et al. 2005).
In this study, depression, the pill burden, and total num-
ber of psychotropic medications were associated with in-
creased irregularity in daily antidepressant dosage, while
euthymia was associated with increased regularity. The
same factors were associated with irregularity in our
prior study of daily mood stabilizer dosage (Bauer et al.
2013b). Evidence from adherence research also supports
these findings. Depression, including residual symptoms,
was associated with nonadherence in bipolar disorder
(Baldessarini et al. 2008b; Johnson et al. 2007; Belzeaux
et al. 2013) and in many general medical conditions
(DiMatteo et al. 2000). Several reports relate nonadher-
ence with medication regimen complexity in bipolar dis-
order (Bauer et al. 2013b; Keck et al. 1996; Lavantes
et al. 1999; Sajatovic et al. 2009), although research on
this issue is limited. An association between medication
regimen complexity and nonadherence was found across
























































Figure 1 Irregularity in antidepressant usage (high ApEn). (A) Bupropion usage. ApEn(1,0.2 × SD,100) = 0.456, 17% missing days, 0 holidays.
(B) Bupropion usage. ApEn(1,0.2 × SD,100) = 0.443, 20% missing days, 4 holidays. (C) Escitalopram usage. ApEn(1,0.2 × SD,100) = 0.541, 24% missing
days, 0 holidays. (D) Escitalopram usage. ApEn(1,0.2 × SD,100) = 0.453, 7% missing days, 0 holidays.
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bipolar disorder for several reasons. The use of polyphar-
macy has increased sharply over the last decade (Mojtabai
and Olfson 2010; Greil et al. 2012; Haeberle et al. 2012),
and many patients must take complex regimens throughout
their lifetime, even when asymptomatic. Although patients
with bipolar disorder frequently have medical comorbidities
(Kilbourne et al. 2004; Krishnan 2005), this study only con-
sidered psychotropic drugs, and regimens may be consider-
ably more onerous when all drugs are included. Medication
regimen complexity would also be expected to increase as
patients age and experience more chronic diseases. In a na-
tionally representative community sample of 3,005 adultsTable 4 Estimated parameter coefficients and significance of
Parameter Coefficient estimate 95%
Total pill burden 0.009
Total number of medications 0.020
Percent days depressed 0.002
Percent days euthymic −0.001
Percent days manic 0.000
aGEE model estimated ApEn (1,0.2 × SD,100) using listed parameters with an indepe
all models.
*Significant < 0.05.over age 57 in the US, 29% used more than five prescription
medications, and about half took over the counter prepara-
tions or supplements (Qato et al. 2008). Finally, an import-
ant characteristic of patients who are adherent to complex
medication regimens is the ability to successfully integrate
the dosing schedule into their daily routine (Ryan and
Wagner 2003; Vrijens et al. 2005). Yet many patients with
bipolar disorder have an unstable lifestyle and a chaotic
daily routine (Frank et al. 2000).
When patients took both an antidepressant and a
mood stabilizer, there was no difference in regularity in
the daily dosage between the drugs. This suggests that
regularity in daily dosage may be independent of the144 patients taking 207 antidepressants for 100 daysa
Wald confidence interval Wald chi-square P
(0.003, 0.015) 8.004 0.005*
(0.006, 0.033) 7.857 0.005*
(<0.001, 0.003) 5.865 0.015*
(−0.003, <0.000) 3.891 0.049*
(−0.004, 0.003) 0.065 0.799
ndent correlation structure for each patient. Degrees of freedom were 1 for
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This finding is consistent with previous work on adher-
ence in patients receiving polypharmacy. Similar nonad-
herence rates were found for both antidepressants and
mood stabilizers in patients with psychiatric disorders
(Bulloch and Patten 2010; Colom et al. 2000), and for
several classes of drugs in patients with bipolar disorder
(Sajatovic et al. 2009). Furthermore, regardless of diag-
nosis, people with chronic illness often experiment with
their medications. Many will alter medication dosage up
or down as they perceive the symptoms are changing
(Pound et al. 2005), or actively minimize intake as a
form of asserting control over a difficult illness (Conrad
1985; Cooper et al. 2007; Pound et al. 2005).
It is not clear how much irregularity in daily dosage will
still provide acceptable therapeutic coverage for the drug
regimens in this study. The relationship between adherence
and outcome is complex, as the pharmacodynamic and
pharmacokinetic properties of the each drug and drug for-
mulation directly impacts the effects of dosing irregularities.
Forgiveness is defined as the difference between the post-
dose duration of beneficial action and the dosing interval,
and varies with half life and dosage strength (Osterberg
et al. 2010; Urquhart 1998). With more forgiving drugs,
drug action may continue when a dose is missed. To ad-
dress the problem of missed doses, many newer drug for-
mulations require less frequent dosing, often once daily.
However, the consequences of missing a dose of a drug
with less frequent administration may be more severe than
for more frequent administration (Comté et al. 2007;
Osterberg et al. 2010). While less frequent dosing does in-
crease adherence (Claxton et al. 2001; Saini et al. 2009), this
often does not lead to improved outcomes for patients with
chronic diseases (Richter et al. 2003). Future studies of the
impact of the frequency of dosing of antidepressants on the
outcome in bipolar disorder are indicated.
The frequency of drug holidays in the short 100-day ana-
lysis periods are of particular concern since abrupt discon-
tinuation of all classes of antidepressants, and especially
short-acting serotonin uptake inhibitors, may trigger
withdrawal reactions (Haddad 2001; Judge et al. 2002;
Rosenbaum et al. 1998). In prior studies of patients with de-
pression, symptoms were milder after abrupt discontinu-
ation of fluoxetine with a long half-life of 2 to 6 days than
after abrupt discontinuation of paroxetine with a half-life of
21 h (Judge et al. 2002; Osterberg et al. 2010; Rosenbaum
et al. 1998). In addition to immediate symptoms related to
drug half-lives, late-appearing symptoms related to long-
term adaptive responses to cerebral pharmacodynamic ef-
fects may also occur (Baldessarini 1995; Baldessarini et al.
2010; Osterberg et al. 2010). Moreover, rapid discontinu-
ation of an antidepressant, rather than gradual tapering, is
associated with a shorter time to depression recurrence in
patients with bipolar disorder (Baldessarini et al. 2010). Forpatients taking antidepressants, investigation of the impact
of drug holidays on the course of bipolar disorder is
needed.
This study may underestimate the irregularity in the
daily antidepressant dosage for several reasons. Dosage
timing was not investigated, as would be possible with
an electronic medication monitor. Since the analysis re-
quired 100 days of data, the least adherent patients were
excluded. Although patients in the complete ChronoRe-
cord database have similar demographic characteristics
to those who participate in other large studies of bipolar
disorder (Bauer et al. 2012), only a subset was included
in this analysis. The subset was predominantly female,
educated, and only failed to take medication on 19% of
days. While the findings may not be generalizable to all
patients with bipolar disorder, even higher irregularity in
the daily antidepressant dosage would be expected in pa-
tients who are less adherent.
There were other limitations to this study. All data were
self-reported. The prescribed dosage for the antidepressant
was not known, although the mean daily dose of each anti-
depressant was in the expected range. Other factors that
impact medication regimen complexity such as instructions
to take drugs separately or with food were not considered
(Libby et al. 2013). Diverse factors that contribute to adher-
ence were not included in this study such as attitudes to-
wards bipolar disorder, psychiatric comorbidities, substance
abuse and psychotic symptoms (Berk et al. 2010; Leclerc
et al. 2013; Keck et al. 1998; Dell'Osso et al. 2002), out-of-
pocket costs of prescription drugs (Piette et al. 2004),
frequency of psychiatric visits (Patel et al. 2005), and the
quality of patient-physician communication (Zolnierek and
DiMatteo 2009). The ApEn technique does not address
causality.
A strength of this study is that the analysis was based
on the daily dose taken by the patient. Most instruments
used to measure adherence in bipolar disorder focus on
the number of missing days and the attitudes and behav-
iors associated with adherence, rather than on what was
ingested (Berk et al. 2010; Sajatovic et al. 2010). Al-
though self-reported instruments are subjective, review
articles on adherence report moderate to high agreement
between self-report and electronic medication monitor-
ing devices (Garber et al. 2004; Shi et al. 2010). Add-
itionally, good agreement between patient questionnaires
and serum drug levels has been reported in bipolar dis-
order (Jónsdóttir et al. 2010; Lam et al. 2003).
Conclusion
In conclusion, considerable irregularity was found in the
daily dosage of antidepressants taken despite a low percent
of days missing doses. Drug holidays were common. De-
pression, the number of daily pills, and the pill burden were
associated with increased irregularity, and euthymia was
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depressants and mood stabilizers, there was no significant
difference in the regularity in daily dosage between these
drugs. Further research is required to identify medication
regimens for bipolar disorder that are more suitable for im-
perfect adherence.
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